• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前列腺癌中窖蛋白-1 的甲基化模式作为潜在的 cfDNA 生物标志物。

Methylation pattern of caveolin-1 in prostate cancer as potential cfDNA biomarker.

机构信息

Department of Biology, University of Zagreb School of Medicine, Zagreb, Croatia; Scientific Group for Research on Epigenetic Biomarkers, University of Zagreb School of Medicine, Zagreb, Croatia; Scientific Centre of Excellence for Reproductive and Regenerative Medicine, University of Zagreb School of Medicine, Zagreb, Croatia.

Ljudevit Jurak Clinical Department of Pathology and Cytology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia.

出版信息

Biomol Biomed. 2023 Feb 1;23(1):176-186. doi: 10.17305/bjbms.2022.7497.

DOI:10.17305/bjbms.2022.7497
PMID:36036057
原文链接:
https://pmc.ncbi.nlm.nih.gov/articles/PMC9901895/
Abstract

High prevalence and mortality of prostate cancer (PCa) are well known global health issues. Novel biomarkers for better identifying patients with PCa are the subject of extensive research. Prostate specific antigen (PSA) shows low specificity in screening and diagnostics, leading to unnecessary biopsies and health costs. Eighty patients with PCa and benign prostate hyperplasia (BPH) were included in the study. We analyzed CAV1 gene expression and methylation in tissue. CAV1 cfDNA methylation from blood and seminal plasma was accessed as a potential PCa biomarker. Although methylation in blood plasma did not differ between PCa and BPH patients, methylation in seminal plasma showed better PCa biomarker performances than tPSA (AUC 0.63 vs. AUC 0.52). Discrimination of BPH and Gleason grade group 1 PCa patients from patients with higher Gleason grade groups revealed very good performance as well (AUC 0.72). CAV1 methylation is useful biomarker with potential for further seminal plasma cfDNA research, but its diagnostic accuracy should be improved, as well as general knowledge about cfDNA in seminal plasma.

摘要

前列腺癌(PCa)的高患病率和死亡率是众所周知的全球健康问题。新型生物标志物可更好地识别 PCa 患者,这是广泛研究的主题。前列腺特异性抗原(PSA)在筛查和诊断中的特异性较低,导致不必要的活检和健康成本增加。本研究纳入了 80 例前列腺癌和良性前列腺增生(BPH)患者。我们分析了组织中的 CAV1 基因表达和甲基化。评估了血液和精液中 CA V1 cfDNA 甲基化作为潜在的前列腺癌生物标志物。虽然 PCa 患者和 BPH 患者的血浆甲基化无差异,但与 tPSA 相比,精液中的甲基化显示出更好的 PCa 生物标志物性能(AUC 0.63 与 AUC 0.52)。从具有更高 Gleason 分级组的患者中区分 BPH 和 Gleason 分级组 1 PCa 患者的表现也非常好(AUC 0.72)。CA V1 甲基化是一种有用的生物标志物,具有进一步研究精液 cfDNA 的潜力,但应提高其诊断准确性,并提高对精液 cfDNA 的一般认识。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d29e/9901895/f7c95c560b4c/bjbms-2022-7497f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d29e/9901895/5b89c5ad17aa/bjbms-2022-7497f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d29e/9901895/487628b8c3e6/bjbms-2022-7497f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d29e/9901895/9448f65713c0/bjbms-2022-7497f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d29e/9901895/88c1c4a99bfd/bjbms-2022-7497f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d29e/9901895/4606f1be8e44/bjbms-2022-7497f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d29e/9901895/f2885fa96f1a/bjbms-2022-7497f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d29e/9901895/c750c0828039/bjbms-2022-7497f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d29e/9901895/f7c95c560b4c/bjbms-2022-7497f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d29e/9901895/5b89c5ad17aa/bjbms-2022-7497f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d29e/9901895/487628b8c3e6/bjbms-2022-7497f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d29e/9901895/9448f65713c0/bjbms-2022-7497f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d29e/9901895/88c1c4a99bfd/bjbms-2022-7497f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d29e/9901895/4606f1be8e44/bjbms-2022-7497f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d29e/9901895/f2885fa96f1a/bjbms-2022-7497f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d29e/9901895/c750c0828039/bjbms-2022-7497f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d29e/9901895/f7c95c560b4c/bjbms-2022-7497f8.jpg

相似文献

1
Methylation pattern of caveolin-1 in prostate cancer as potential cfDNA biomarker.前列腺癌中窖蛋白-1 的甲基化模式作为潜在的 cfDNA 生物标志物。
Biomol Biomed. 2023 Feb 1;23(1):176-186. doi: 10.17305/bjbms.2022.7497.
2
LGALS3 cfDNA methylation in seminal fluid as a novel prostate cancer biomarker outperforming PSA.精液中 LGALS3 的 cfDNA 甲基化作为一种新型前列腺癌生物标志物,优于 PSA。
Prostate. 2024 Sep;84(12):1128-1137. doi: 10.1002/pros.24749. Epub 2024 Jun 2.
3
Seminal Cell Free DNA Concentration Levels Discriminate Between Prostate Cancer and Benign Prostatic Hyperplasia.精浆游离DNA浓度水平可区分前列腺癌和良性前列腺增生。
Anticancer Res. 2018 Sep;38(9):5121-5125. doi: 10.21873/anticanres.12833.
4
Prognostic significance of epithelial/stromal caveolin-1 expression in prostatic hyperplasia, high grade prostatic intraepithelial hyperplasia and prostatic carcinoma and its correlation with microvessel density.上皮/基质小窝蛋白-1在前列腺增生、高级别前列腺上皮内瘤变及前列腺癌中的预后意义及其与微血管密度的相关性
J Egypt Natl Canc Inst. 2017 Mar;29(1):25-31. doi: 10.1016/j.jnci.2017.01.002. Epub 2017 Mar 1.
5
Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia.血清生物标志物联合检测在鉴别前列腺癌与前列腺增生中的临床应用价值。
Sci Rep. 2021 Jul 23;11(1):15052. doi: 10.1038/s41598-021-94438-4.
6
Using Genetic and Epigenetic Markers to Improve Differential Diagnosis of Prostate Cancer and Benign Prostatic Hyperplasia by Noninvasive Methods in Mexican Patients.利用遗传和表观遗传标志物通过非侵入性方法改善墨西哥患者前列腺癌和良性前列腺增生的鉴别诊断。
Clin Genitourin Cancer. 2018 Aug;16(4):e867-e877. doi: 10.1016/j.clgc.2018.02.004. Epub 2018 Feb 27.
7
Detection of Cancer-Associated Gene Mutations in Urinary Cell-Free DNA among Prostate Cancer Patients in South Africa.南非前列腺癌患者尿游离 DNA 中与癌症相关的基因突变检测。
Genes (Basel). 2023 Sep 27;14(10):1884. doi: 10.3390/genes14101884.
8
Quick assessment of cell-free DNA in seminal fluid and fragment size for early non-invasive prostate cancer diagnosis.快速评估精液中的游离 DNA 和片段大小,用于早期非侵袭性前列腺癌的诊断。
Clin Chim Acta. 2019 Oct;497:76-80. doi: 10.1016/j.cca.2019.07.011. Epub 2019 Jul 10.
9
Total thiol can contribute to differentiating prostate cancer from BPH: Prostate Thiol Index as a new player.总巯基有助于区分前列腺癌和 BPH:前列腺巯基指数作为新的指标。
Andrologia. 2021 Nov;53(10):e14190. doi: 10.1111/and.14190. Epub 2021 Jul 16.
10
Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?游离或复合前列腺特异性抗原(PSA)与总PSA的比值:哪种比值能改善良性前列腺增生与前列腺癌之间的鉴别诊断?
Clin Chem. 2000 Jan;46(1):55-62.

引用本文的文献

1
Circulating Tumor DNA in Prostate Cancer: A Dual Perspective on Early Detection and Advanced Disease Management.前列腺癌中的循环肿瘤DNA:早期检测与晚期疾病管理的双重视角
Cancers (Basel). 2025 Aug 6;17(15):2589. doi: 10.3390/cancers17152589.
2
cfMethylPre: deep transfer learning enhances cancer detection based on circulating cell-free DNA methylation profiling.cfMethylPre:深度迁移学习基于循环游离DNA甲基化谱分析增强癌症检测。
Brief Bioinform. 2025 May 1;26(3). doi: 10.1093/bib/bbaf303.
3
Advance in prostate cancer biomarker discovery: bridging detection, prognosis and therapeutics.

本文引用的文献

1
The utility of cfDNA in TGCT patient management: a systematic review.循环游离DNA在睾丸生殖细胞肿瘤患者管理中的应用:一项系统评价
Ther Adv Med Oncol. 2022 May 25;14:17588359221090365. doi: 10.1177/17588359221090365. eCollection 2022.
2
Low-Grade Prostate Cancer: Time to Stop Calling It Cancer.低级别前列腺癌:是时候不再称其为癌症了。
J Clin Oncol. 2022 Sep 20;40(27):3110-3114. doi: 10.1200/JCO.22.00123. Epub 2022 Apr 18.
3
A protocol for good quality genomic DNA isolation from formalin-fixed paraffin-embedded tissues without using commercial kits.
前列腺癌生物标志物发现的进展:连接检测、预后与治疗
Discov Oncol. 2025 May 30;16(1):954. doi: 10.1007/s12672-025-02763-1.
4
Recent advances on gene-related DNA methylation in cancer diagnosis, prognosis, and treatment: a clinical perspective.癌症诊断、预后及治疗中基因相关DNA甲基化的最新进展:临床视角
Clin Epigenetics. 2025 May 5;17(1):76. doi: 10.1186/s13148-025-01884-2.
5
Molecular pathogenesis, mechanism and therapy of Cav1 in prostate cancer.Cav1在前列腺癌中的分子发病机制、作用机制及治疗
Discov Oncol. 2023 Nov 1;14(1):196. doi: 10.1007/s12672-023-00813-0.
一种无需使用商业试剂盒,从福尔马林固定石蜡包埋组织中提取高质量基因组 DNA 的方案。
Mol Biol Rep. 2022 May;49(5):4115-4121. doi: 10.1007/s11033-022-07394-1. Epub 2022 Apr 1.
4
Heat Shock Proteins in Benign Prostatic Hyperplasia and Prostate Cancer.热休克蛋白在良性前列腺增生和前列腺癌中的作用。
Int J Mol Sci. 2022 Jan 14;23(2):897. doi: 10.3390/ijms23020897.
5
Locus-Specific Methylation of GSTP1, RNF219, and KIAA1539 Genes with Single Molecule Resolution in Cell-Free DNA from Healthy Donors and Prostate Tumor Patients: Application in Diagnostics.健康供体和前列腺肿瘤患者游离DNA中GSTP1、RNF219和KIAA1539基因位点特异性甲基化的单分子分辨率研究:在诊断中的应用
Cancers (Basel). 2021 Dec 12;13(24):6234. doi: 10.3390/cancers13246234.
6
Immunohistochemical Evaluation of PARP and Caspase-3 as Prognostic Markers in Prostate Carcinomas.免疫组织化学评估 PARP 和 Caspase-3 作为前列腺癌的预后标志物。
Clin Med Res. 2021 Dec;19(4):183-191. doi: 10.3121/cmr.2021.1607.
7
Somatic driver mutation prevalence in 1844 prostate cancers identifies ZNRF3 loss as a predictor of metastatic relapse.在 1844 例前列腺癌中检测到体细胞驱动突变的流行率,确定 ZNRF3 缺失可作为转移性复发的预测因子。
Nat Commun. 2021 Oct 29;12(1):6248. doi: 10.1038/s41467-021-26489-0.
8
Impact of Preanalytical and Analytical Methods on Cell-Free DNA Diagnostics.分析前和分析方法对游离DNA诊断的影响。
Front Cell Dev Biol. 2021 Sep 6;9:686149. doi: 10.3389/fcell.2021.686149. eCollection 2021.
9
Bridging the Gaps between Circulating Tumor Cells and DNA Methylation in Prostate Cancer.弥合前列腺癌循环肿瘤细胞与DNA甲基化之间的差距
Cancers (Basel). 2021 Aug 21;13(16):4209. doi: 10.3390/cancers13164209.
10
Post-Biopsy Cell-Free DNA From Blood: An Open Window on Primary Prostate Cancer Genetics and Biology.活检后血液中的游离DNA:打开原发性前列腺癌遗传学与生物学的一扇窗。
Front Oncol. 2021 May 24;11:654140. doi: 10.3389/fonc.2021.654140. eCollection 2021.